VedaBio: Rashid Bashir, Daniel Durocher, Patrick Hsu, David Perlin

VedaBio, a San Diego-based developer of multiplexed CRISPR-based molecular detection technology, has formed its scientific advisory board comprising Rashid Bashir, Daniel Durocher, Patrick Hsu, and David Perlin.

Bashir is a company cofounder and was recently elected to the National Academy of Medicine. He has held numerous roles at the University of Illinois at Urbana-Champaign, currently serving as the dean of the Grainger College of Engineering and Grainger distinguished chair in bioengineering.

Durocher is chair of VedaBio's SAB and currently serves as senior investigator at the Lunenfeld-Tanenbaum Research Institute, cofounder and SAB member of Repare Therapeutics, and cofounder of Induxion Therapeutics. He is also a full professor at the University of Toronto.

Hsu is cofounder of the Arc Institute and assistant professor of bioengineering and a faculty fellow at the University of California, Berkeley. Previously, he served as principal investigator at the Salk Institute for Biological Studies.

Perlin currently serves as CSO and executive VP at Hackensack Meridian Health Center for Discovery and Innovation.

VedaBio launched last month with $40 million in Series A financing.